Wall Street brokerages expect that Flexion Therapeutics Inc (NASDAQ:FLXN) will announce earnings of ($1.06) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Flexion Therapeutics’ earnings. The highest EPS estimate is ($1.04) and the lowest is ($1.08). Flexion Therapeutics reported earnings of ($1.16) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 8.6%. The company is scheduled to report its next earnings results after the market closes on Tuesday, August 6th.
On average, analysts expect that Flexion Therapeutics will report full-year earnings of ($4.07) per share for the current financial year, with EPS estimates ranging from ($4.18) to ($3.93). For the next year, analysts expect that the business will post earnings of ($2.44) per share, with EPS estimates ranging from ($2.95) to ($1.68). Zacks’ EPS calculations are an average based on a survey of analysts that follow Flexion Therapeutics.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.04. Flexion Therapeutics had a negative net margin of 549.07% and a negative return on equity of 131.94%. The firm had revenue of $10.56 million during the quarter, compared to analyst estimates of $11.10 million.
Several brokerages recently commented on FLXN. Northland Securities reaffirmed a “buy” rating and set a $20.00 price target on shares of Flexion Therapeutics in a research report on Thursday, May 9th. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 23rd. Laidlaw set a $18.00 price target on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Thursday, April 11th. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. Finally, Benchmark raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $23.71.
FLXN stock traded down $0.70 on Friday, hitting $9.07. 976,666 shares of the company were exchanged, compared to its average volume of 504,384. Flexion Therapeutics has a twelve month low of $8.98 and a twelve month high of $24.42. The company has a debt-to-equity ratio of 2.10, a current ratio of 6.32 and a quick ratio of 6.06. The company has a fifty day simple moving average of $10.94. The firm has a market cap of $381.45 million, a PE ratio of -2.02 and a beta of 1.38.
In other Flexion Therapeutics news, CFO David Arkowitz acquired 2,500 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was bought at an average cost of $11.05 per share, for a total transaction of $27,625.00. Following the completion of the purchase, the chief financial officer now directly owns 89,424 shares in the company, valued at $988,135.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael D. Clayman acquired 4,012 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were acquired at an average price of $12.48 per share, with a total value of $50,069.76. Following the completion of the purchase, the insider now owns 74,868 shares of the company’s stock, valued at $934,352.64. The disclosure for this purchase can be found here. Insiders have purchased 18,512 shares of company stock valued at $226,775 in the last ninety days. 16.01% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Services Advisors Inc. grew its stake in Flexion Therapeutics by 46.2% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 106,164 shares of the specialty pharmaceutical company’s stock worth $1,325,000 after buying an additional 33,569 shares during the period. Claro Advisors LLC grew its stake in Flexion Therapeutics by 33.0% during the first quarter. Claro Advisors LLC now owns 22,150 shares of the specialty pharmaceutical company’s stock worth $276,000 after buying an additional 5,500 shares during the period. Geode Capital Management LLC grew its stake in Flexion Therapeutics by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 384,433 shares of the specialty pharmaceutical company’s stock worth $4,351,000 after buying an additional 7,814 shares during the period. D. E. Shaw & Co. Inc. grew its stake in Flexion Therapeutics by 516.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 250,402 shares of the specialty pharmaceutical company’s stock worth $2,835,000 after buying an additional 209,809 shares during the period. Finally, Alps Advisors Inc. grew its stake in Flexion Therapeutics by 4.5% during the first quarter. Alps Advisors Inc. now owns 91,439 shares of the specialty pharmaceutical company’s stock worth $1,141,000 after buying an additional 3,952 shares during the period. Institutional investors own 89.15% of the company’s stock.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Story: What is a capital gains distribution?
Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.